Smith Opposes Speaker Pelosi’s Government Takeover Drug Pricing Bill

Washington, D.C. – Congressman Adrian Smith (R-NE) released the following statement regarding Speaker Pelosi's Drug Pricing Bill (H.R. 3), which is expected to be voted on later this week:

"Speaker Pelosi's attempt to socialize American medicine undoes the bipartisan work on lowering drug pricing policies which was well under way. We should not be outsourcing our drug pricing policies from countries with socialized healthcare. H.R. 3 will keep seniors from accessing some vital medications, impede competition in the marketplace, and stifle development of new cures."

Congressman Smith is an original cosponsor of the Lower Costs, More Cures Act (H.R. 19), an alternative to Speaker Pelosi's plan. H.R. 19 contains commonsense bipartisan provisions, which had been a focal point in the Committee on Ways and Means up until the introduction of H.R. 3. In addition to providing immediate relief from high prescription drug costs, H.R. 19 has the votes to pass the Senate – unlike H.R. 3.